Search

A summer program offers college students from underrepresented communities a chance to get valuable research experience.

Fred’s Team, MSK’s running program, has made history by surpassing $100 million in total funds raised for cancer research.

OncoKB®, a precision oncology knowledge database developed by MSK researchers and physicians, has received partial recognition status from the US Food and Drug Administration (FDA).

New MSK research discovers a new approach that could prevent chemotherapy-related leukemia; shows how monoclonal antibodies can turn neutrophils into cancer killers; helps develop sensitive CAR T cells that target CD70 antigen to destroy cancer cells; and uses single-cell studies to yield new clues about a rare, aggressive pediatric sarcoma.

The initial results of an ongoing study show that a liquid biopsy has advantages over a tissue biopsy for people with lung cancer.

Maria Jasin’s discoveries have led to concrete advances in patient care. The targeted medicines called PARP inhibitors, for example, are based on knowledge gained from her work.

MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.

Dimiter Tassev, a member of Gerstner Sloan Kettering's inaugural class, has completed all his degree requirements and will receive his PhD in May.